HERCULES, CA--(Marketwired - Jan 16, 2017) - Bio-Rad Laboratories, Inc. (
Based in Billerica, Massachusetts, RainDance Technologies' foundational intellectual property portfolio and product lines encompass a wide range of biological reactions in droplets, with applications in life science research and clinical research. These genomic tools provide ultra-sensitive detection of genetic variations in cancer as well as inherited and infectious diseases, enabling research in areas such as non-invasive liquid biopsy.
"We are pleased to have RainDance join Bio-Rad," said Norman Schwartz, Bio-Rad President and CEO. "The company's droplet-based solutions will extend our reach into next-generation sequencing applications and strengthen our position in the area of Droplet Digital ™ PCR. We look forward to expanding our offering to provide life science and clinical diagnostics customers with solutions for a wide range of nucleic acid detection applications."
About RainDance Technologies Based in Billerica, Massachusetts, RainDance Technologies offers a proprietary droplet technology that enables research in areas such as non-invasive liquid biopsy. These ultra-sensitive genomic tools that include RainDrop ® Digital PCR, ThunderStorm ® , and ThunderBolts ™ Next-Generation Sequencing Enrichment, offer accurate, reliable, and cost-effective detection of genetic variations in cancer as well as inherited and infectious diseases. RainDance customers include research institutions and laboratories around the world.
About Bio-Rad
Bio-Rad Laboratories, Inc. (
This release may be deemed to contain certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements generally can be identified by the use of forward-looking terminology such as, "believe," "expect," "anticipate," "may," "will," "intend," "estimate," "continue," or similar expressions or the negative of those terms or expressions, although not all forward-looking statements contain these words. Such statements involve risks and uncertainties, which could cause actual results to vary materially from those expressed in or indicated by the forward-looking statements. For further information regarding the Company's risks and uncertainties, please refer to the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operation" in Bio-Rad's public reports filed with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K and our Quarterly Reports on Form 10-Q. Bio-Rad cautions you not to place undue reliance on forward-looking statements, which reflect an analysis only and speak only as of the date hereof. We disclaim any obligation to update these forward-looking statements.
Press Contact: Bio-Rad Laboratories, Inc. Tina Cuccia Corporate Communications 510-724-7000 Email Contact
